The study of fibrinogen replacement to prevent intracranial haemorrhage in ischemic stroke

The company Azienda Usl di Bologna is commencing recruitment for the clinical trial of the Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER).

The conditions are Intracranial Hemorrhages, Ischemic Stroke.

A new clinical trial is recruiting patients in the following locations: Italy.

The trial officially began on the February 8, 2022 and is planned to complete on December 31, 2024.

Fibrinogen replacement could prevent haemorrhagic complications in ischemic stroke patients with secondary post-rtPA hypofibrinogenemia

Ministero della Salute, Italy is the collaborator in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05300672.

Clinical Research News

今後の臨床試験

3